APRE — Aprea Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $21.72m
- -$9.34m
- $0.58m
- 25
- 24
- 48
- 23
Annual cashflow statement for Aprea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.1 | -53.5 | -37.1 | -113 | -14.3 |
| Depreciation | |||||
| Non-Cash Items | 0.177 | 6.07 | 7.76 | 89.4 | 0.483 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.16 | 5.57 | -8.33 | -1.76 | 1.62 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -26.7 | -41.8 | -37.7 | -25 | -12.2 |
| Capital Expenditures | -0.031 | -0.026 | 0 | 0 | -0.093 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.031 | -0.026 | 0 | 0 | -0.093 |
| Financing Cash Flow Items | — | — | — | — | -0.649 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 92.6 | 0.151 | 1.75 | 0.683 | 5.14 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 64.4 | -41.1 | -35.9 | -24.3 | -7.14 |